Noile-Immune Biotech Inc.'s (TSE:4893) Path To Profitability

With the business potentially at an important milestone, we thought we'd take a closer look at Noile-Immune Biotech Inc.'s (TSE:4893) future prospects. Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. With the latest financial year loss of JP¥793m and a trailing-twelve-month loss of JP¥754m, the JP¥3.8b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Noile-Immune Biotech's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to some industry analysts covering Noile-Immune Biotech, breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of JP¥1.4b in 2028. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow -6.3% year-on-year, on average,

Given this is a high-level overview, we won’t go into details of Noile-Immune Biotech's upcoming projects, however, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, periods of lower growth in the upcoming years is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for Noile-Immune Biotech

Before we wrap up, there’s one aspect worth mentioning. Noile-Immune Biotech currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are key fundamentals of Noile-Immune Biotech which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Noile-Immune Biotech, take a look at Noile-Immune Biotech's company page on Simply Wall St. We've also compiled a list of key aspects you should further examine:

1. Historical Track Record: What has Noile-Immune Biotech's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Noile-Immune Biotech's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.